UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15

UBS maintained a Buy on Kura Oncology on March 13, 2026, while lowering its price target to $15, shaping the current KURA analyst rating. This move keeps exposure to Kura’s oncology pipeline but signals UBS sees less near-term upside than before. The note drove a modest intraday move, with a 1.11% change equal to $0.10. Meyka AI rates KURA with a grade of B based on S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus